Urteste S.A. (WSE: URT)
Health Care · Biotechnology · PL
zł43.70
+0.23% today · -15.8% 1Y
Urteste S.A. (WSE: URT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.89M and employs 38 people.
Over the last twelve months the share price has lost 15.8%, trading between 24.00 and 72.20.
Tweenvest scores Urteste S.A. across four factors: quality 39/100, value 53/100. Its strongest factor is value.
URT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.89M
- Revenue (TTM)
- $669.66K
- P/E
- —
- EPS
- -4.94
- Dividend yield
- —
- Beta (5Y)
- 0.21
- 52-week high
- zł72.20
- 52-week low
- zł24.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.53M
- Employees
- 38
- Next earnings
- —
About Urteste S.A.
Urteste S.A. focuses on the investigation and development of diagnostic solutions designed to detect various forms of cancer. Their portfolio includes testing methods for a wide range of malignancies affecting organs such as the pancreas, prostate, kidneys, colon, liver, biliary system, stomach, lungs, esophagus, ovaries, endometrium, blood, breasts, and the nervous system. This enterprise, based in Gdansk, Poland, commenced its operations in 2021.
- ISIN
- PLURTST00010
- Founded
- 2021
- Listed since
- Oct 27, 2021
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.